JP2005511642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005511642A5 JP2005511642A5 JP2003546936A JP2003546936A JP2005511642A5 JP 2005511642 A5 JP2005511642 A5 JP 2005511642A5 JP 2003546936 A JP2003546936 A JP 2003546936A JP 2003546936 A JP2003546936 A JP 2003546936A JP 2005511642 A5 JP2005511642 A5 JP 2005511642A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- formula
- compound
- pharmaceutically acceptable
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 15
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 10
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 6
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 6
- 229960002216 methylparaben Drugs 0.000 claims description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 4
- 229960003415 propylparaben Drugs 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 6
- 239000004067 bulking agent Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000003085 diluting agent Substances 0.000 claims 4
- 230000002335 preservative Effects 0.000 claims 4
- 239000003755 preservative agent Substances 0.000 claims 4
- 206010060945 Bacterial infection Diseases 0.000 claims 3
- 241000282472 Canis lupus familiaris Species 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N M-Cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 2
- 235000019445 benzyl alcohol Nutrition 0.000 claims 2
- 229960004217 benzyl alcohol Drugs 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 claims 1
- 229960001950 Benzethonium Chloride Drugs 0.000 claims 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M Benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 210000001635 Urinary Tract Anatomy 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000007979 citrate buffer Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 2
- 230000004059 degradation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 1
- KRCMKUNIILUXPF-UHFFFAOYSA-N methyl 4-hydroxybenzoate;sodium Chemical compound [Na].COC(=O)C1=CC=C(O)C=C1 KRCMKUNIILUXPF-UHFFFAOYSA-N 0.000 description 1
- 238000005020 pharmaceutical industry Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
Description
表5に示すように、処方物4および5(それぞれpH5.1および6.0、表3から)は、許容される長期安定性を有していた(すなわち、25℃で18ヶ月後の分解は10%未満である)。しかしながら、4.1未満またはそれと等しいpHを有する処方物は、製薬工業において医薬生成物にとって典型的に許容されない10%を超える分解を示した。しかしながら、表4に示すように、クエン酸塩緩衝剤を利用した処方物の最適安定性は、約6.0〜約7.0のpHであった。
実施例5
化合物Iのナトリウム塩およびメチルパラベン(1.8mg/mL)のAET
化合物Iのナトリウム塩(80mg/mL)およびメチルパラベン(1.8mg/mL)を20mMクエン酸塩緩衝液中に含有する溶液について、AETを行った。AETの結果を表9に示す。この処方物は、全ての微生物に対してUSP基準を満たした(許容基準については表14参照)。さらに、この処方物は、6および24時間の時点での黄色ブドウ球菌を除き、全ての微生物に対して基準Aを満たした。
化合物Iのナトリウム塩およびメチルパラベン(1.8mg/mL)のAET
化合物Iのナトリウム塩(80mg/mL)およびメチルパラベン(1.8mg/mL)を20mMクエン酸塩緩衝液中に含有する溶液について、AETを行った。AETの結果を表9に示す。この処方物は、全ての微生物に対してUSP基準を満たした(許容基準については表14参照)。さらに、この処方物は、6および24時間の時点での黄色ブドウ球菌を除き、全ての微生物に対して基準Aを満たした。
実施例6
化合物Iのナトリウム塩、メチルパラベン(1.8mg/mL)およびプロピルパラベン(0.2mg/mL)のAET
化合物Iのナトリウム塩(80mg/mL)、メチルパラベン(1.8mg/mL)およびプロ
ピルパラベン(0.2mg/mL)を20mMクエン酸塩緩衝液中に含有する溶液について、E
PおよびUSP手順に従ってAETを行った。AETの結果を表10に示す。この処方物は、全ての微生物に対してUSP基準を満たした(許容基準については表14参照)。さらに、この処方物は、6および24時間の時点での黄色ブドウ球菌を除き、全ての微生物
に対してEP基準Aを満たした。
化合物Iのナトリウム塩、メチルパラベン(1.8mg/mL)およびプロピルパラベン(0.2mg/mL)のAET
化合物Iのナトリウム塩(80mg/mL)、メチルパラベン(1.8mg/mL)およびプロ
ピルパラベン(0.2mg/mL)を20mMクエン酸塩緩衝液中に含有する溶液について、E
PおよびUSP手順に従ってAETを行った。AETの結果を表10に示す。この処方物は、全ての微生物に対してUSP基準を満たした(許容基準については表14参照)。さらに、この処方物は、6および24時間の時点での黄色ブドウ球菌を除き、全ての微生物
に対してEP基準Aを満たした。
Claims (15)
- M+がNa+であり、そしてpHが6.0〜7.5である、請求項1に記載の医薬組成物。
- 選択自由な製薬上許容される緩衝剤、選択自由な製薬上許容される保存剤、選択自由な製薬上許容される増量剤、および水性希釈剤をさらに含む、請求項1または2に記載の医薬組成物。
- 組成物が1を超えて10未満の増量剤/式Iの化合物の比を有する、請求項1〜4の何れかに記載の医薬組成物。
- 増量剤がショ糖であり、そして組成物が3のショ糖/式Iの化合物の比を有する、請求項5に記載の医薬組成物。
- 選択自由な製薬上許容される緩衝剤、選択自由な製薬上許容される保存剤、および水性希釈剤をさらに含む、請求項4、5または6の何れかに記載の医薬組成物。
- 保存剤がメチルパラベン、プロピルパラベン、m−クレゾール、塩化ベンザルコニウム、塩化ベンゼトニウムまたはベンジルアルコール、またはその2種またはそれ以上の組み合わせである、請求項1〜7の何れかに記載の医薬組成物。
- 保存剤が、(a)メチルパラベン、プロピルパラベンおよびベンジルアルコール;または(b)メチルパラベンおよびm−クレゾールの何れか一方の組み合わせである、請求項8に記載の医薬組成物。
- 請求項1〜9の何れかに記載の医薬組成物の凍結乾燥により製造された式Iの化合物を含む医薬組成物。
- M+がNa+である、請求項11に記載の使用。
- 請求項1〜10の何れかに記載の医薬組成物からなるイヌおよびネコにおける細菌感染に起因する状態を治療または予防するための医薬。
- 状態が皮膚、軟組織または尿路の細菌感染である、請求項13に記載の医薬。
- 状態または感染がグラム陽性菌またはグラム陰性菌に起因するか、またはそれらが合併したものである、請求項13または14に記載の医薬。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33853601P | 2001-11-30 | 2001-11-30 | |
US60/338,536 | 2001-11-30 | ||
US39893202P | 2002-07-26 | 2002-07-26 | |
US60/398,932 | 2002-07-26 | ||
PCT/IB2002/004743 WO2003045435A1 (en) | 2001-11-30 | 2002-11-13 | Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005511642A JP2005511642A (ja) | 2005-04-28 |
JP2005511642A5 true JP2005511642A5 (ja) | 2006-01-12 |
JP4689959B2 JP4689959B2 (ja) | 2011-06-01 |
Family
ID=26991236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003546936A Expired - Lifetime JP4689959B2 (ja) | 2001-11-30 | 2002-11-13 | セファロスポリン化合物を含む処方物ならびにイヌおよびネコにおける細菌感染の治療におけるその使用 |
Country Status (28)
Country | Link |
---|---|
US (1) | US7378408B2 (ja) |
EP (1) | EP1448234B1 (ja) |
JP (1) | JP4689959B2 (ja) |
KR (1) | KR100621291B1 (ja) |
CN (1) | CN100502873C (ja) |
AR (1) | AR037595A1 (ja) |
AT (1) | ATE406916T1 (ja) |
AU (1) | AU2002348986B2 (ja) |
BR (1) | BRPI0214583B1 (ja) |
CA (1) | CA2468708C (ja) |
CY (1) | CY1108437T1 (ja) |
DE (1) | DE60228749D1 (ja) |
DK (1) | DK1448234T3 (ja) |
EA (1) | EA008503B1 (ja) |
ES (1) | ES2307800T3 (ja) |
HK (1) | HK1071292A1 (ja) |
HR (1) | HRP20040487A2 (ja) |
IL (2) | IL161851A0 (ja) |
IS (1) | IS7214A (ja) |
MA (1) | MA27085A1 (ja) |
MX (1) | MXPA04003724A (ja) |
NO (1) | NO334818B1 (ja) |
NZ (1) | NZ532208A (ja) |
PL (1) | PL212683B1 (ja) |
PT (1) | PT1448234E (ja) |
TN (1) | TNSN04097A1 (ja) |
TW (1) | TWI248363B (ja) |
WO (1) | WO2003045435A1 (ja) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20021725A1 (it) | 2002-08-01 | 2002-10-31 | Zambon Spa | Composizioni farmaceutiche ad attivita' antibiotica. |
EP1740214B1 (en) * | 2004-04-22 | 2007-10-03 | Pfizer Products Incorporated | Method of stabilizing disordered cefovecin sodium salt |
EP1656930A1 (en) * | 2004-11-10 | 2006-05-17 | Basilea Pharmaceutica AG | Stabilized freeze-dried formulation for cephalosporin derivatives |
CA2591157C (en) * | 2004-12-17 | 2012-06-12 | Venus Remedies Limited | Antibiotic combinations for providing total solution to the treatment of infections |
CN101080221A (zh) * | 2005-02-14 | 2007-11-28 | 维纳斯药业有限公司 | 抗药性细菌感染疾病的肠胃外综合治疗 |
PT1945223E (pt) * | 2005-10-29 | 2010-10-14 | Intervet Int Bv | Composições de cefquinoma e métodos para a sua utilização |
US20080103121A1 (en) * | 2006-10-30 | 2008-05-01 | Gole Dilip J | Cephalosporin derivative formulation |
KR20100137439A (ko) * | 2008-03-04 | 2010-12-30 | 엘란 파마 인터내셔널 리미티드 | 항감염제의 안정성 액체 포뮬레이션 및 항감염제의 조정된 용량투여 요법 |
CN101352422B (zh) * | 2008-09-17 | 2011-04-20 | 厦门朝阳生物工程有限公司 | 河豚毒素冻干粉针制剂及其制备方法 |
US8256233B2 (en) | 2008-10-31 | 2012-09-04 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
US8731841B2 (en) | 2008-10-31 | 2014-05-20 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
US9050070B2 (en) | 2008-10-31 | 2015-06-09 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
US8798932B2 (en) | 2008-10-31 | 2014-08-05 | The Invention Science Fund I, Llc | Frozen compositions and methods for piercing a substrate |
US9056047B2 (en) | 2008-10-31 | 2015-06-16 | The Invention Science Fund I, Llc | Compositions and methods for delivery of frozen particle adhesives |
US8788211B2 (en) * | 2008-10-31 | 2014-07-22 | The Invention Science Fund I, Llc | Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition |
US8731840B2 (en) | 2008-10-31 | 2014-05-20 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
US9060926B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
US8725420B2 (en) | 2008-10-31 | 2014-05-13 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
US20100111857A1 (en) | 2008-10-31 | 2010-05-06 | Boyden Edward S | Compositions and methods for surface abrasion with frozen particles |
US8731842B2 (en) | 2008-10-31 | 2014-05-20 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
US9050317B2 (en) | 2008-10-31 | 2015-06-09 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
US9060934B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
US9072688B2 (en) | 2008-10-31 | 2015-07-07 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
US9072799B2 (en) | 2008-10-31 | 2015-07-07 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
US8762067B2 (en) | 2008-10-31 | 2014-06-24 | The Invention Science Fund I, Llc | Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data |
US8721583B2 (en) | 2008-10-31 | 2014-05-13 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
US8793075B2 (en) | 2008-10-31 | 2014-07-29 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
US9060931B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for delivery of frozen particle adhesives |
US20140274997A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Cephalosporin pharmaceutical compositions |
US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
CA2906151A1 (en) * | 2013-03-15 | 2014-09-18 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
ES2968237T3 (es) * | 2015-07-09 | 2024-05-08 | Uniwell Laboratories Llc | Composiciones farmacéuticas |
JP7020913B2 (ja) | 2015-09-07 | 2022-02-16 | 持田製薬株式会社 | アルギン酸凍結乾燥製剤 |
KR20200091396A (ko) * | 2017-09-27 | 2020-07-30 | 페도라 파마슈티칼스 인코포레이티드 | 디아자비시클로옥탄 유도체의 약제학적 형태 및 그의 제조 방법 |
EP3687992A1 (en) | 2017-09-27 | 2020-08-05 | Meiji Seika Pharma Co., Ltd. | Crystalline forms of diazabicyclooctane derivatives and production process thereof |
WO2019064066A1 (en) | 2017-09-27 | 2019-04-04 | F. Hoffmann-La Roche Ag | PHARMACEUTICAL FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF |
GB2575261B (en) | 2018-07-02 | 2022-03-09 | Norbrook Lab Ltd | Intermediates in the synthesis of C3-substituted cephalosporins |
CN109393004A (zh) * | 2018-09-28 | 2019-03-01 | 上海锦立保鲜科技有限公司 | 一种利用冻品自由水升华实现真空解冻的方法 |
AU2022396967A1 (en) * | 2021-11-26 | 2024-06-13 | Astellas Pharma Inc. | Indocyanine compound-containing solid pharmaceutical composition |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4002748A (en) | 1976-01-19 | 1977-01-11 | Eli Lilly And Company | Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration |
JPS5711909A (en) | 1980-06-23 | 1982-01-21 | Shionogi & Co Ltd | Stable freeze-dried preparation of beta-lactam |
JPS6045514A (ja) | 1983-08-22 | 1985-03-12 | Shionogi & Co Ltd | 安定な抗菌性凍結乾燥製剤 |
SE8500273D0 (sv) * | 1985-01-22 | 1985-01-22 | Leo Ab | Nya tricykliska foreningar, kompositioner innehallande sadana foreningar, framstellningsforfaranden och behandlingsmetoder |
US5138066A (en) | 1987-08-14 | 1992-08-11 | Hoffmann-La Roche, Inc. | Intermediates for cephalosporins with sulfur-containing oxyimino side chain |
SU1750429A3 (ru) | 1988-02-05 | 1992-07-23 | Эли Лилли Энд Компани (Фирма) | Способ получени кристаллического 2,5-гидрата-1-карбацефалоспорина |
CA2024587A1 (en) * | 1989-09-05 | 1991-03-06 | Bernard Ecanow | Drug delivery compositions based on biological cells or components thereof and methods |
US6020329A (en) | 1990-07-24 | 2000-02-01 | Pzifer Inc. | Cephaloporins and homologues, preparations and pharmaceutical compositions |
MY106399A (en) | 1990-07-24 | 1995-05-30 | Pfizer | Cephalosporins and homologeus, preparation and pharmaceutical composition |
US6001997A (en) | 1990-07-24 | 1999-12-14 | Bateson; John Hargreaves | Cephalosporins and homologues, preparations and pharmaceutical compositions |
US5401842A (en) | 1992-09-08 | 1995-03-28 | Bristol-Myers Squibb Company | Injectable compositions of a cephalosporin dihydrate salt |
EP0664117A1 (de) * | 1994-01-25 | 1995-07-26 | F. Hoffmann-La Roche Ag | Liposomenlösungen |
US5665760A (en) * | 1995-09-18 | 1997-09-09 | Sanofi Winthrop, Inc. | Lyophilized thioxanthenone antitumor agents |
KR100312622B1 (ko) * | 1998-11-03 | 2002-02-28 | 김송배 | 생약을주성분으로한안정화된항암제조성물및그제조방법 |
JP2001199889A (ja) * | 1999-11-11 | 2001-07-24 | Takeda Chem Ind Ltd | 縮合ピリダジン誘導体を含有してなる点鼻用剤 |
ATE311227T1 (de) | 1999-12-01 | 2005-12-15 | Natco Pharma Ltd | Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne |
GB0002835D0 (en) * | 2000-02-09 | 2000-03-29 | Melvin William T | Drug resistance in cancer |
GB0019124D0 (en) | 2000-08-03 | 2000-09-27 | Pfizer | Novel process |
HUP0400642A3 (en) * | 2000-12-04 | 2010-03-29 | Pfizer Prod Inc | Coupling process and intermediates useful for preparing cephalosphorins |
-
2002
- 2002-11-12 US US10/292,343 patent/US7378408B2/en not_active Expired - Lifetime
- 2002-11-13 AU AU2002348986A patent/AU2002348986B2/en not_active Expired
- 2002-11-13 CN CNB028229258A patent/CN100502873C/zh not_active Expired - Lifetime
- 2002-11-13 DK DK02781499T patent/DK1448234T3/da active
- 2002-11-13 ES ES02781499T patent/ES2307800T3/es not_active Expired - Lifetime
- 2002-11-13 PL PL370083A patent/PL212683B1/pl unknown
- 2002-11-13 KR KR1020047008097A patent/KR100621291B1/ko active Protection Beyond IP Right Term
- 2002-11-13 JP JP2003546936A patent/JP4689959B2/ja not_active Expired - Lifetime
- 2002-11-13 EA EA200400489A patent/EA008503B1/ru unknown
- 2002-11-13 DE DE60228749T patent/DE60228749D1/de not_active Expired - Lifetime
- 2002-11-13 AT AT02781499T patent/ATE406916T1/de active
- 2002-11-13 CA CA002468708A patent/CA2468708C/en not_active Expired - Lifetime
- 2002-11-13 BR BRPI0214583A patent/BRPI0214583B1/pt active IP Right Grant
- 2002-11-13 EP EP02781499A patent/EP1448234B1/en not_active Expired - Lifetime
- 2002-11-13 IL IL16185102A patent/IL161851A0/xx unknown
- 2002-11-13 MX MXPA04003724A patent/MXPA04003724A/es active IP Right Grant
- 2002-11-13 PT PT02781499T patent/PT1448234E/pt unknown
- 2002-11-13 NZ NZ532208A patent/NZ532208A/en not_active IP Right Cessation
- 2002-11-13 WO PCT/IB2002/004743 patent/WO2003045435A1/en active IP Right Grant
- 2002-11-19 TW TW091133707A patent/TWI248363B/zh not_active IP Right Cessation
- 2002-11-28 AR ARP020104594A patent/AR037595A1/es not_active Application Discontinuation
-
2004
- 2004-04-07 IS IS7214A patent/IS7214A/is unknown
- 2004-05-06 IL IL161851A patent/IL161851A/en active IP Right Grant
- 2004-05-20 MA MA27689A patent/MA27085A1/fr unknown
- 2004-05-28 TN TNP2004000097A patent/TNSN04097A1/fr unknown
- 2004-05-31 HR HR20040487A patent/HRP20040487A2/hr not_active Application Discontinuation
- 2004-06-01 NO NO20042271A patent/NO334818B1/no not_active IP Right Cessation
-
2005
- 2005-05-13 HK HK05104040.7A patent/HK1071292A1/xx not_active IP Right Cessation
-
2008
- 2008-10-21 CY CY20081101180T patent/CY1108437T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005511642A5 (ja) | ||
AU2017201670B2 (en) | A composition comprising an antibiotic and a dispersant or an anti-adhesive agent | |
JP5866298B2 (ja) | 抗菌剤およびその使用法 | |
JP2009509956A (ja) | 非イオン性界面活性剤を使用して中耳内への経膜的薬物送達を促進する、中耳炎の処置および予防のための方法 | |
KR101052705B1 (ko) | 아미노글리코시드계 항생물질 및 브롬페낙을 함유하는수용액 제제 | |
EP1175217B8 (en) | (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents | |
US11779559B2 (en) | Compositions for treating fungal and bacterial biofilms and methods of using the same | |
US6017912A (en) | Topical fluoroquinolone antibiotics in an alcohol and acetone vehicle | |
US20060093573A1 (en) | Drug composition with antimicrobial activity | |
HK1045464A1 (en) | Use of sulfodehydroabietic acid for the treatment of inflammatory bowel disease | |
US20040096521A1 (en) | Method and composition for treating hairy hoof warts | |
JP4685242B2 (ja) | ヒアルロン酸を用いた放射線膀胱炎の予防、軽減、および治療法 | |
AR018335A1 (es) | Compuesto carbapenico, agente antibacteriano que lo comprende y compuesto carbapenico util como intermediario para la obtencion del primero | |
CN1682703A (zh) | 一种杀菌凝胶剂 | |
EP1121940A1 (en) | Pharmaceutical compositions comprising an antibiotic and bromhexine, and process for their preparation | |
US20090124632A1 (en) | Methods and kits related to the topical administration of quinolone antibiotics° | |
KR101392285B1 (ko) | 이중층 구조를 갖는 위체류성 서방성 제제 | |
Kosmidis et al. | Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection | |
JP2022523975A (ja) | 微生物除去 | |
RU2005130771A (ru) | Композиции и способы профилактики и лечения эндотоксин-связанных заболеваний и состояний | |
JP3054758B2 (ja) | 外傷用組成物 | |
US20150010479A1 (en) | Treatment of microbial infections | |
US20030073625A1 (en) | Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial IB-367 peptides | |
JP6748339B2 (ja) | フィナフロキサシンおよびトリスを含む組成物 | |
JP2944759B2 (ja) | 抗菌性組成物 |